

***In vitro* Antimicrobial Screening of *Hedwigia ciliata* Var. *leucophaea* and Determination of the Ethanol Extract Composition by Gas Chromatography/Mass Spectrometry (GC/MS)**

**Kerem Canli^{1*}, Barbaros Cetin¹, Ergin Murat Altuner²,
Yavuz Türkmen³, Ugur Uzek³ and Hayrettin Dursun³**

¹Dokuz Eylül University, Faculty of Science, Department of Biology, Buca, Izmir, Turkey.

²Kastamonu University, Faculty of Science and Arts, Department of Biology,
Kuzeykent, TR-37100, Kastamonu, Turkey.

³Ankara Police Forensic Laboratories, Golbasý Campus of the General Directorate of Security,
TR-06830, Ankara, Turkey.

(Received: 23 January 2014; accepted: 19 March 2014)

Many plants contain active substances that are known to be effective in both enhancing the wound healing process and lowering the incidence of wound infections. Previous studies have shown that bryophytes produce a variety of secondary metabolites that present pharmaceutical activities including antimicrobial activity against various pathogenic bacteria and fungi. The aim of this study was to investigate the antimicrobial activity of *Hedwigia ciliata* var. *leucophaea* (*Hc*) against 17 bacterial and 1 fungal strains and analyse the composition by GC/MS. *Hc* samples were collected from Akdag Mountain (Amasya, TURKEY) and subjected to ethanol extraction after air drying. The *in vitro* antimicrobial activities of *Hc* extracts having 9 mg.mL⁻¹ concentrations were assessed against a wide range of strains by disk diffusion method and the results were supported by a MIC (minimum inhibitory concentration) test. Our present study has shown that the ethanol extract of *Hc* has antimicrobial activity against several Gram positive and Gram negative microorganisms tested, but its antimicrobial activity is notable especially against *B. subtilis*, *E. faecalis*, *S. carnosus*, and *S. epidermidis*. These results are the very first report of the antimicrobial activity of *Hc* and its composition. The results obtained herein indicate that ethanol extract of *Hc* contains several active metabolites and it is active against several microorganisms. But further researches, especially cytotoxicity and genotoxicity tests are needed to be conducted to conclude whether *Hc* extracts can be used safely in terms of their antimicrobial activity.

Key words: *Hedwigia ciliata* var. *leucophaea*, Bryophyte, Antimicrobial activity, Disk diffusion test, Bacterial strains, Fungal strains.

It has been known for years that mosses were used to treat cardiovascular diseases, tonsillitis, bronchitis, cystitis and skin infections especially in traditional Chinese medicine. In addition, previous studies presented that some of the secondary metabolites produced by mosses

are effective in wound healing process and have anti-infective effect on some microorganisms (Altuner *et al.*, 2010).

The anti-infective activities of plant-derived products come up focus of interest in recent years. Increasing morbidity and mortality rates of bacterial and fungal infections and accelerating antibacterial and antifungal resistance rates of microorganisms lead to the research on new antimicrobial agents (Altuner *et al.*, 2010).

* To whom all correspondence should be addressed.
E-mail:biyoloji@gmail.com

The secondary metabolites synthesized by plants which are often used as a defence mechanism against microorganisms, insects and herbivores (Samidurai and Saravanakumar, 2009, Altuner *et al.*, 2012c). These secondary metabolites have some applications such as being used as antimicrobial agents. The antimicrobial activity of plants has many applications, including raw and processed food preservation, pharmaceuticals, alternative medicine and natural therapies (Lis-Balchin and Deans, 1997; Reynolds, 1996).

Bryophytes are plants which define about 14,500 species (Veljic *et al.*, 2008). In contrast to the extensive utilisation of higher plants as a source of antimicrobial substances, Bryophytes have rarely been considered for this purpose (Basile *et al.*, 1998).

It has been known for centuries that mosses are effective in both wound healing process and lowering the risk of infection. In the previous studies it has been presented that some secondary metabolites extracted from mosses have anti-infective effect on some bacteria and fungi (Basile *et al.*, 1998; Ilhan *et al.*, 2006; Veljic *et al.*, 2008; Altuner, 2008; Altuner & Cetin, 2009; Altuner *et al.*, 2010a,b,c, 2011a; Savaroglu *et al.*, 2011a,b; Onbasili *et al.*, 2011,2013; Oztopcu-Vatan *et al.*, 2011; Altuner & Canli, 2012).

It has been known for years that mosses were used to treat cardiovascular diseases, tonsillitis, bronchitis, cystitis and skin infections especially in traditional Chinese medicine. North American Indians were used some bryophytes, such as *Bryum*, *Mnium* and *Philonotis*, to heal burns, bruises and wounds (Saroya, 2011).

Since antibacterial and antifungal resistance has been developing in human pathogens against commonly used antibiotics, there is a need for a search about new antimicrobial substances from other sources including plants (Erdogru, 2002).

Hedwigia ciliata var. *leucophaea* (Family: *Hedwigiaceae* Schimp.) (*Hc*) is a well-known species, easily recognised by its whitish colour, growing over dry acidic rocks. *Hc* is differentiated with a longer hyaline upper part of leaves and strongly papillose leaf cells. *Hc* mainly grows on exposed rocks and prefer base-rich habitats. Although it is reported from Europe, North America and North Africa previously, it's a rare

variety (Smith, 2004).

In this study, antimicrobial activity of *Hc* was determined against 17 bacterial and 1 fungal strains. *Hc* samples which were collected from Akdag Mountain (Amasya) were air dried and extracted with ethanol. The *in vitro* antimicrobial effect of *Hc* were investigated against a wide range of strains such as *Bacillus subtilis* ATCC 6633, *Candida albicans* ATCC 10231, *Enterobacter aerogenes* ATCC13048, *Enterococcus durans*, *Enterococcus faecalis* ATCC 29212, *Enterococcus faecium*, *Escherichia coli* ATCC 25922, *Escherichia coli* CFAI, *Klebsiella pneumoniae*, *Listeria monocytogenes* ATCC 7644, *Salmonella enteritidis* ATCC 13075, *Salmonella infantis*, *Salmonella kentucky*, *Salmonella typhimurium* SL 1344, *Staphylococcus aureus* ATCC 25923, *Staphylococcus carnosus* MC1.B, *Staphylococcus epidermidis* DSMZ 20044 and *Streptococcus agalactiae* DSMZ 6784 by using the disk diffusion method and the results were supported by a minimum inhibitory concentration (MIC) test.

MATERIALS AND METHODS

Moss Samples

Hedwigia ciliata var. *leucophaea* Bruch & Schimp. samples used in this study were collected from Akdag Mountain (N 40° 442 - E 035° 592), Amasya, which is located between Central Anatolia and the Middle Black Sea region. Voucher specimens were deposited for further reference.

Extraction Procedure

All *Hc* samples were dried out after collection and the samples were ground by a mortar and a pestle. In order to extract active substances, ethanol (Merck, Germany) was chosen as an extraction solvent. Ground samples were shaken in ethanol at 100 rpm for 3 days at room temperature. All the extracts were filtered through Whatman No. 1 filter paper into evaporation flasks (Altuner *et al.*, 2011b). The filtrate was evaporated by a rotary evaporator (Heidolph Hei-Vap Value HL/HB-G1) at 30°C. After evaporation the residues were collected and used to prepare 9 mg.mL⁻¹ extracts.

Microorganisms

A wide range of Gram positive and Gram negative bacteria and yeast were selected to test

the antimicrobial effect of *Hc*. The strains were chosen from standard strains as much as possible. Other strains which are not standard were all isolated from food and identified in Ankara University, Faculty of Science, Department of Biology.

Bacillus subtilis ATCC 6633, *Candida albicans* ATCC 10231, *Enterobacter aerogenes* ATCC13048, *Enterococcus durans*, *Enterococcus faecalis* ATCC 29212, *Enterococcus faecium*, *Escherichia coli* ATCC 25922, *Escherichia coli* CFAI, *Klebsiella pneumoniae*, *Listeria monocytogenes* ATCC 7644, *Salmonella enteritidis* ATCC 13075, *Salmonella infantis*, *Salmonella kentucky*, *Salmonella typhimurium* SL 1344, *Staphylococcus aureus* ATCC 25923, *Staphylococcus carnosus* MC1.B, *Staphylococcus epidermidis* DSMZ 20044 and *Streptococcus agalactiae* DSMZ 6784 were used in the study.

Preparation of Inocula

All bacterial strains were incubated at 37 °C for 24 h. But since the requirements for *C. albicans* is different, *C. albicans* was inoculated at 27 °C for 48 h. Inocula were prepared by transferring morphologically similar colonies of each organism into 0.9% sterile saline solution until the visible turbidity was equal to 0.5 McFarland standard having approximately 10^8 cfu.mL⁻¹ for bacteria and 10^7 cfu.mL⁻¹ for *C. albicans* (Hammer et. al, 1999; Altuner, 2011).

Disk Diffusion Method

Disk diffusion test was performed as described previously by Andrews (2003). The culture medium was poured into 120 mm sterile Petri dish to give a mean depth of 4.0 mm ± 0.5 mm (Altuner and Çetin, 2009; Altuner and Akata, 2010). 60 µL, 100 µL and 150 µL aliquots of each extract was applied on sterile paper disks of 6 mm diameter end up with 550 µg.µL⁻¹, 917 µg.µL⁻¹ and 1375 µg.µL⁻¹ sample on each disk (Mahasneh and El-Oqlah, 1999; Silici and Koc, 2006). To get rid of any residual solvent which might interfere with the results, disks were left to dry overnight at 30°C in sterile conditions (Silici and Koc, 2006; Altuner et al., 2012a,b). The surface of the plates was inoculated using previously prepared inocula containing saline suspension of microorganisms. Inoculated plates were then left to dry for 5 minutes

at room temperature before applying the disks. Disks were firmly applied to the surface of the plate which had an even contact with the agar. Plates were incubated and inhibition zone diameters were expressed in millimetres.

Determination of MIC

Broth dilution method for Minimum Inhibitory Concentration (MIC) determination as described in Basile et al. (1998) was performed. Serial 2-fold dilutions were made to obtain a concentration range of 3.9 - 2000 µg.mL⁻¹. The MIC was defined as the lowest concentration of extract inhibiting any visible bacterial growth.

Gas Chromatography-Mass Spectrometry Method (GC-MS)

The GC-MS analysis of ethanol extract of *Hc* were quantitatively performed by GC-MS (Agilent 19091S-433, 30x0.25x0.25 HPS MS) based on the method defined previously by Hossain and Rahman (2011) with some modifications. Split less injection was performed with a purge time of 1.0 min. The carrier gas was helium at a flow rate of 1 mL.min⁻¹. The column temperature was maintained at 60 °C for 2 minutes, then programmed at 10 °C.min⁻¹ to 300 °C and waited for 10 minutes. The inlet temperature was 250 °C, AUX was 290 °C and the solvent delay was 4 min. The identification of the peaks was based on computer matching of the mass spectra with the National Institute of Standards and Technology (NIST Mass Spectrometry DATA CENTER, 2005) library and by direct comparison with published data (Karimi and Jaafar, 2011).

Controls

Empty sterile disks and extraction solvent (ethanol) loaded on sterile disks which were dried at sterile conditions to remove solvent as done in the study were used as negative controls.

Statistics

The statistical analysis was performed using a non-parametric method Kruskal-Wallis one-way analysis of variance. A value of $P < 0.05$ was considered statistically significant.

RESULTS

The diameter of the inhibition zones recorded as the diameter of the zones in millimetres for the samples are given in Table 1 and the MIC

values for the microorganisms in which activity was observed in disk diffusion test are given in Table 2.

No activity was observed for the negative controls; solvents and empty sterile disks.

Table 1 clearly shows that ethanol extracts of *Hc* were presented antimicrobial activity against *B. subtilis* ATCC 6633, *E. aerogenes* ATCC 13048, *E. faecalis* ATCC 29212, *E. faecium*, *S. typhimurium* SL 1344, *S. carnosus* MC1.B, *S. epidermidis* DSMZ 20044 and *S. agalactiae* DSMZ 6784.

According to the data presented in Table 2, the lowest activity was observed in *S. typhimurium* SL 1344 by 1000 µg.mL⁻¹ of *Hc* extract, where the highest activity was observed in *B. subtilis* ATCC 6633 by 62.5 µg.mL⁻¹ of *Hc* extract.

The GC-MS analysis of ethanol extract of *Hc* is given in Table 3. The ethanol extract of *Hc* is found to be composed of acetic acid, silane, triethoxymethyl, tetraethyl silicate, 1,1-diethoxypentane, hepta-2,4-dienal, d-limonene, 1,2,4,5-tetramethylbenzene, 1-ethyl-2,3-dimethylbenzene, benzoic acid, ethyl ester, 4-methyl benzoic acid, hexose, maltol, orcinolaldehyde, diethyltoluamide, tetradecanoic acid (myristic acid), 2-phenylmethyl 1,3-cyclohexanedione, dihydrophytol, γ-palmitolactone, farnesol isomer

a, n-hexadecanoic acid, hexadecanoic acid, manoyl oxide, doconexent, kaurene, γ-stearolactone, transphytol, linoleic acid, octadecanoic acid, linoleic acid ethyl ester, monopalmitin, monostearin, squalene, α-tocopherol, campesterol, stigmaterol, obtusifoliol, γ-sitosterol, isofucosterol, cycloartenol, vitamin-E acetate, sitostenone, dihydroxyacetone (oxetane), delta-3-carene, phytol and stearic acid.

DISCUSSION

Results given in Table 1 and Table 2 clearly show that *Hc* are active against several microorganisms but its antimicrobial activity is notable especially against *B. subtilis* ATCC 6633, *E. faecalis* ATCC 29212, *S. carnosus* MC1.B and *S. epidermidis* DSMZ 20044.

There have been no reports about the antimicrobial activity of *Hc* as far as the current literature is concerned. These results are the very first data about the antimicrobial activity of *Hc* and its composition.

Among the microorganisms which were affected by *Hc* extracts *B. subtilis* ATCC 6633, *E. faecalis* ATCC 29212, *E. faecium*, *S. carnosus* MC1.B and *S. epidermidis* DSMZ 20044 are gram positive where *E. aerogenes* ATCC13048 and *S. typhimurium* SL 1344 are gram negative strains.

It is a well known fact that Gram negative bacteria are in general more resistant to a large number of antibiotics and chemotherapeutic agents than Gram positive bacteria (Nikaido, 1998). In addition, it was also pointed out previously that Gram negative bacteria are the dominant killers among bacterial pathogens in the Intensive Care Units (ICU) (Villegas and Quinn, 2004).

Table 1. Disk diffusion test results (Inhibition zones in mm)

	60µL	100µL	150µL
<i>B. subtilis</i> ATCC 6633	-	-	16
<i>C. albicans</i> ATCC 10231	-	-	-
<i>E. aerogenes</i> ATCC13048	7	7	7
<i>E. durans</i>	-	-	-
<i>E. faecalis</i> ATCC 29212	-	-	12
<i>E. faecium</i>	-	-	7
<i>E. coli</i> ATCC 25922	-	-	-
<i>E. coli</i> CFAI	-	-	-
<i>K. pneumoniae</i>	-	-	-
<i>L. monocytogenes</i> ATCC 7644	-	-	-
<i>S. enteritidis</i> ATCC 13075	-	-	-
<i>S. infantis</i>	-	-	-
<i>S. kentucky</i>	-	-	-
<i>S. typhimurium</i> SL 1344	-	-	7
<i>S. aureus</i> ATCC 25923	-	-	-
<i>S. carnosus</i> MC1.B	-	8	11
<i>S. epidermidis</i> DSMZ 20044	-	9	15
<i>S. agalactiae</i> DSMZ 6784	7	9	8

"-": No activity observed.

Table 2. MIC values (µg.mL⁻¹)

	MIC (µg.mL ⁻¹)
<i>B. subtilis</i> ATCC 6633	62.5
<i>E. aerogenes</i> ATCC13048	500
<i>E. faecalis</i> ATCC 29212	125
<i>E. faecium</i>	500
<i>S. typhimurium</i> SL 1344	1000
<i>S. carnosus</i> MC1.B	125
<i>S. epidermidis</i> DSMZ 20044	125
<i>S. agalactiae</i> DSMZ 6784	250

Table 3. Chemical composition of *Hc* and their composition percentages.

No	Compounds	Composition (%)
1	acetic acid	0.96
2	silane, triethoxymethyl	0.04
3	tetraethyl silicate	0.22
4	1,1-diethoxyptane	0.04
5	hepta-2,4-dienal	0.08
6	d-limonene	0.04
7	1,2,4,5-tetramethylbenzene	0.06
8	1-ethyl-2,3-dimethylbenzene	0.10
9	benzoic acid, ethyl ester	0.08
10	4-methyl benzoic acid	0.10
11	hexose	2.00
12	maltol	1.02
13	orcinaldehyde	0.06
14	diethyltoluamide	0.02
15	tetradecanoic acid (myristic acid)	0.08
16	2-phenylmethyl 1,3- -cyclohexanedione	0.12
17	dihydrophytol	0.20
18	γ -palmitolactone	0.08
19	farnesol isomer a	0.42
20	n-hexadecanoic acid	0.68
21	hexadecanoic acid	7.02
22	manoyl oxide	0.06
23	doconexent	0.48
24	kaurene	0.06
25	γ -stearolactone	0.14
26	transphytol	0.08
27	linoleic acid	1.94
28	octadecanoic acid	0.30
29	linoleic acid ethyl ester	3.58
30	monopalmitin	0.90
31	monostearin	2.48
32	squalene	1.82
33	α -tocopherol	0.74
34	campesterol	4.56
35	stigmasterol	2.60
36	obtusifoliol	0.38
37	γ -sitosterol	1.96
38	isofucosterol	0.22
39	cycloartenol	0.22
40	vitamin-E acetate	0.18
41	sitostenone	0.18
42	dihydroxyacetone (oxetane)	2.06
43	delta-3-carene	1.92
44	phytol	2.70
45	stearic acid	3.02

E. aerogenes was previously identified as one of the “ICU bugs” which could cause significant morbidity and mortality. In addition the infection management is complicated due to its resistance to multiple antibiotics (Hidron *et al.*, 2008). Although a very low activity was observed against *E. aerogenes*, the results can be accepted as noteworthy. Probably increasing amount of extracts loaded on the empty sterile antibiotic disks may increase the activity

It was reported that although serovar Typhimurium of *Salmonella* has a less alarming public image than serovar Typhi, it is a bigger health problem and it is thought by researchers to be at least 30-fold underreported. There are probably hundreds of millions of cases every year in the world in which serovar Typhimurium kill twice as many people as serovar Typhi which were mostly infants and the elderly people (McClelland *et al.*, 2001). According to results, 100 μ L of *Hc* extract showed very low antibacterial activity against *S. typhimurium* SL 1344. Since the inhibition zone is quite low, increasing the active substance loaded on the empty sterile antibiotic disks may also increase the activity.

On the other hand *ethanol* extracts of *Hc* are active against several gram positive strains, as stated previously. The results of the disk diffusion tests applied on the gram positive strains are more remarkable than the results of gram negative strains. The activity against especially on *B. subtilis* ATCC 6633, *E. faecalis* ATCC 29212, *S. carnosus* MC1.B and *S. epidermidis* DSMZ 20044 are noteworthy.

The pathogenic potential of *B. subtilis* is generally described as low or absent (De Boer and Diderichsen, 1991). *B. subtilis* is only known to cause disease in severely immunocompromised patients (Galieni and Bigazzi, 1998). Several researchers study antimicrobial activity of some plant extracts on *B. subtilis* ATCC 6633. Khalid *et al.* (2011) compared four different methanolic plant extracts, namely *Pistacia integerrim*, *Polygonum bistorta*, *Swertia chirata* and *Zingiber officinale*. In this study maximum 30 mg of extracts were loaded on sterile antibiotic disks and inhibition zones were found to be 12 mm for *P. integerrim*, 11 mm for *P. bistorta*, 12 mm for *S. chirata* and 17 mm for *Z. officinale*. In our study we observed 16 mm zone for 1.375 mg of *Hc* extract which is about 22 times

lower than the amount used for study conducted by Khalid *et al.* (2011). Comparing these results clearly puts forward how *Hc* is active against *B. subtilis* when compared to some other higher plants.

E. faecalis can cause endocarditis and bacteremia, urinary tract infections, meningitis and other infections in humans (Murray, 1990). It is associated with nosocomial infections including catheter-associated urinary tract infections, central line-associated bloodstream infection and surgical site infections (Hidron *et al.*, 2008).

Khalid *et al.* (2011) also studied the activity of some higher plants on *E. faecalis* but used ATCC 14506 strain. Again 30 mg of extracts were loaded on sterile antibiotic disks and inhibition zones were found to be 10 mm for *P. integerrim*, 13 mm for *P. bistorta* and 8 mm for *Z. officinale* and no activity was observed against *S. chirata*. In our study we observed 12 mm zone for 1.375 mg of *Hc* extract. Some other researches about the antimicrobial effect of *Hypericum triquetrifolium*, *Hypericum perforatum* and *Hypericum empetrifolium* against *E. faecalis* ATCC 29212 presented an activity 9 mm, 10 mm and 8 mm of zones respectively.

According to these results it can be concluded that *ethanol* extracts of *Hc* is more active than some higher plants against *E. faecalis* ATCC 29212, which is also true for *B. subtilis*.

S. epidermidis is not usually pathogenic. But they often develop risk for infection for patients with a compromised immune system. These infections can be both nosocomial or community acquired, but they pose a greater threat to hospital patients. *S. epidermidis* is also a major concern for people with catheters or other surgical implants because it is known to cause biofilms that grow on these devices (Queck and Otto, 2008; Salyers *et al.*, 2002).

Several studies conducted on the antimicrobial activity of several higher plants against *S. epidermidis*. Mahida and Mohan (2007) tested 10 mg of methanolic extracts of 23 plant extracts, but the highest zone was found to be 20 mm for *Mangifera indica*. In another study *ethanol* extracts of 23 plants were tested against *S. epidermidis* and the highest inhibition zone diameter was given as 18 mm for *Stachys leptoclada* (Sarac and Ugur, 2007).

In our study we observed a 15 mm inhibition zone for 1.375 mg of *Hc* extract against *S. epidermidis* DSMZ 20044 which is relatively high when compared to other previous studies.

The antimicrobial nature of *Hc* extract can be explained by looking at Table 3. The GC/MS analysis clearly puts forward the composition of *Hc* extract, which contains several compounds that have antimicrobial activities.

Dihydroxyacetone (1,3-Dihydroxypropan-2-one) (DHA), which is also known as glycerone in *Hc* is a simple carbohydrate. It is a triose, having formula $C_3H_6O_3$ (Budavari, 1996). DHA was first recognized as a skin colouring agent and also used as an oral drug for assisting children with glycogen storage disease (Wittgenstein and Berry, 1960; Wittgenstein and Guest, 1961; Goldman *et al.*, 1961). In addition to these properties DHA has also antimicrobial activity. Manuka honeys containing DHA presented antimicrobial activity especially against multi-resistant strains of *S. aureus*, *S. epidermidis*, *E. coli* and *Pseudomonas aeruginosa* (Lukowski *et al.*, 2008; Mavric, 2008; Adams *et al.*, 2009; Bäcker *et al.*, 2010).

Carene (3,7,7-trimethylbicyclo[4.1.0]hept-3-ene) which is also known as delta-3-carene ($C_{10}H_{16}$), is a bicyclic monoterpene which can be a skin irritant or CNS depressant. Cosentino *et al.* (2003) showed that *Juniperus turbinata* essential oils are active against fungi, particularly against a strain of *Aspergillus flavus*. In addition, they tested antimicrobial activity of single compounds which are present in significant quantities in oils. They proved that delta-3-carene possesses the broadest antimicrobial activity and appeared to contribute significantly to the antifungal activity of *J. turbinata* oils (Cosentino *et al.*, 2003). Pauli (2006) also found that delta-3-carene is active especially against *Candida utilis*.

Maltol (3-hydroxy-2methyl-4H-pyran-4-one) is neutral, heterocyclic compound having formula as $C_6H_6O_3$. It is also known as larixic acid and widely used as food additive, antioxidant and metal ions chelator (Samejo *et al.*, 2009). Some pharmacological activities of maltol have been reported (Aoyagi *et al.*, 1974; Soulimani *et al.*, 1997), such as showing a central depressing activity (Kimura *et al.*, 1980; Aytemir *et al.*, 2004). In addition, some maltol derivatives were proved

to have antimicrobial activity especially against *C. albicans* and *S. aureus* (Fassih et al., 2009).

Tetradecanoic acid, which is also called myristic acid, is a saturated fatty acid having molecular formula $\text{CH}_3(\text{CH}_2)_{12}\text{COOH}$. It is previously presented that myristic acid is an antibacterial and antifungal agent (McGaw, 2002; Seidel and Taylor, 2004; Agoramoorthy et al., 2007). Skrivanova (2006) showed that myristic acid has antimicrobial activity against *Clostridium perfringens*. Batovska et al. (2009) found that myristic acid is active against *L. monocytogenes* with having $125 \mu\text{g}\cdot\text{mL}^{-1}$ MIC value. Narasimhan et al. (2006) tested the antimicrobial activity of myristic acid derivatives and presented that myristic acid derivatives are more effective against Gram positive bacteria rather than Gram negative bacteria. It is also concluded that *S. aureus* is the most sensitive organism to myristic acid derivatives (Narasimhan et al., 2006). It is also reported that myristic acid has antifungal activity against *Alternaria solani* (Liu et al., 2008), *Aspergillus niger* (Altieri et al., 2007; Carballeira et al., 2005), *Candida albicans* (Kabara et al., 1972), *Emericella nidulans* (Altieri et al., 2007), *Fusarium oxysporum* (Liu et al., 2008), *Penicillium glabrum* (Altieri et al., 2007), *Penicillium italicum* (Altieri et al., 2007).

Phytol ((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-ol) is an acyclic diterpene alcohol having molecular formula $\text{C}_{20}\text{H}_{40}\text{O}$. It is commercially utilised in the fragrance industry and also in cosmetics, shampoos, toilet soaps, household cleaners, and detergents (McGinty et al., 2010). Phytol is also reported for its antimicrobial, antiviral, diuretic, anti-inflammatory, strong antioxidant and anti-tumoral activities (Alfred, 2002; Kumar et al., 2010; Padmini et al., 2010; Uma et al., 2011; Revathi et al., 2012). Phytol is found to be active especially against *S. aureus* (Inoue et al., 2005).

Campesterol ((24R)-Ergost-5-en-3 β -ol) is a phytosterol having molecular formula $\text{C}_{28}\text{H}_{48}\text{O}$. It has a chemical structure similar to that of cholesterol. It is recommended as a treatment for especially hypercholesterolemia (Párraga et al., 2011). Animal studies have presented that campesterol can reduce the size of atherogenic plaques and it can also reduce atherosclerosis, heart disease and cardiac events (Clifton, 2009). In addition, Singh et al. (2011) showed that

campesterol has a notable antifungal activity especially against *C. albicans*.

Gamma-sitosterol is a phytosterol which is C-24 isomer of betasitosterol. It is present in many plants (Raman et al., 2012). Gamma-sitosterol is known to be used as a phytomedicine to treat especially ulcers, bronchitis, diabetes and heart diseases (Balamurugan et al., 2011). Gamma-sitosterol is also reported to be used as a folklore medicine because of its very strong antifungal, antibacterial and anti-angiogenic activity (Zhang and Zhou, 2011).

Stigmasterol is one of other phytosterol which is also known as Wulzen anti-stiffness factor. It has a molecular formula $\text{C}_{29}\text{H}_{48}\text{O}$ and it is also chemically similar to animal cholesterol. Stigmasterol is mostly used in producing semi-synthetic progesterone as a precursor (Sundaraman and Djerassi, 1977; PBS, 2007). Recent researches showed that stigmasterol can be used in prevention of certain cancers, inhibiting several pro-inflammatory and matrix degradation mediators which are involved in osteoarthritis-induced cartilage degradation and it also possesses antioxidant, anti-rheumatic, hypoglycemic and thyroid inhibiting properties (Budavari, 1989; Gallina et al., 2007; Panda et al., 2009). In addition, stigmasterol was previously reported as an antimicrobial agent (Prachayasittikul et al., 2009, 2012).

Hexadecanoic acid, which is also known as palmitic acid, is the most common fatty acid found in animals, plants and microorganisms (Gunstone et al., 2007). It is mainly used to produce soaps and cosmetics. Hexadecanoic acid is also proposed as an antimicrobial agent in several researches (Glover et al., 1997; Risk et al., 1997; Bazes et al., 2009). Hexadecanoic acid also presented a significant antibacterial activity against *Streptococcus mutans* (Huang et al., 2011). In addition, it has antifungal activity against *Alternaria solani* (Liu et al., 2008), *Aspergillus niger* (Altieri et al., 2007), *Aspergillus terreus* (Altieri et al., 2007), *Cucumerinum lagenarium* (Liu et al., 2008), *Emericella nidulans* (Liu et al., 2008), *Fusarium oxysporum* (Liu et al., 2008).

Stearic acid is a saturated fatty acid having molecular formula $\text{C}_{18}\text{H}_{36}\text{O}_2$. Stearic acid is mainly used in the production of detergents, soaps and cosmetics, but an antimicrobial activity potential

against diverse pathogenic microorganism is also proposed in several studies (Zheng *et al.*, 2005; Nalina and Rahim; 2007; Chakraborty and Shah, 2011).

Antimicrobial activity of linoleic acid was also determined in several researches. Tsuchida and Morishida (1995) investigated its antimicrobial activity against some Gram positive and Gram negative strains. They found that linoleic acid has high antimicrobial activity mostly against Gram positive strains. It also presented antimicrobial activity against *Bacillus larvae* (Feldlaufer *et al.*, 1993). It is also identified that linoleic acid is active against *Alternaria solani* (Liu *et al.*, 2008), *Candida albicans* (Kabara *et al.*, 1972), *Crinipellis perniciosa* (Walters *et al.*, 2004), *Fusarium oxysporum* (Liu *et al.*, 2008), *Pyrenophora avariae* (Walters *et al.*, 2004), *Pythium ultimum* and *Rhizoctonia solani* (Walters *et al.*, 2004).

It is also previously reported that linoleic acid has antibacterial activity (Knapp and Melly, 1986; Kabara *et al.*, 1972; Hazell and Graham, 1990; Sun *et al.*, 2003; Zheng *et al.*, 2005) and antifungal activity against *Crinipellis perniciosa*, *Pyrenophora avariae*, *Pythium ultimum* and *Rhizoctonia solani* (Walters *et al.*, 2004).

In our study we observed antimicrobial activity against *B. subtilis*, *E. aerogenes*, *E. faecalis*, *E. faecium*, *S. typhimurium*, *S. carnosus*, *S. epidermidis* and *S. agalactiae*. But we did not observed any activity against *C. albicans*, *E. durans*, *E. coli*, *K. pneumoniae*, *L. monocytogenes*, *S. enteritidis*, *S. infantis*, *S. kentucky*, *S. aureus* in any concentrations tested.

There is no information about the antimicrobial activities of the metabolites found in the composition of *Hc* extract against *B. subtilis*, *E. aerogenes*, *E. faecalis*, *E. faecium*, *S. typhimurium*, *S. carnosus* and *S. agalactiae*. But according to the previous studies, an activity against *S. epidermidis* is not a surprise, because DHA is proposed to be active against *S. epidermidis* (Lukowski *et al.*, 2008; Mavric, 2008; Adams *et al.*, 2009; Bäcker *et al.*, 2010).

The main surprise in our study is not observing any antimicrobial activity against *S. aureus*, *C. albicans*, *E. coli* and *L. monocytogenes*.

Batovska *et al.* (2009) proposed that myristic acid is active against *L. monocytogenes*. In addition DHA is stated to be active against *E.*

coli (Lukowski *et al.*, 2008; Mavric, 2008; Adams *et al.*, 2009; Bäcker *et al.*, 2010).

Previous studies stated that DHA (Lukowski *et al.*, 2008; Mavric, 2008; Adams *et al.*, 2009; Bäcker *et al.*, 2010), maltol derivatives (Fassihi *et al.*, 2009), myristic acid derivatives (Narasimhan *et al.*, 2006) and phytol (Inoue *et al.*, 2005) are active against *S. aureus*. Also, maltol derivatives (Fassihi *et al.*, 2009), myristic acid (Kabara *et al.*, 1972) and campesterol (Singh *et al.*, 2011) are found to be active against *C. albicans*.

The reason of not observing any activity against *S. aureus*, *C. albicans*, *E. coli* and *L. monocytogenes* could possibly either due to the concentration of the metabolites in the *Hc* extract or the strains, which could be resistant to the metabolites.

The results obtained herein indicate that ethanol extract of *Hc* contains several active metabolites and it is active against several microorganisms. Its antimicrobial activity is notable especially against *B. subtilis*, *E. faecalis*, *S. carnosus* and *S. epidermidis* when both disk diffusion test and MIC values are taken into account. But further researches especially cytotoxicity and genotoxicity tests are needed to be conducted to conclude whether *Hc* extracts can be used safely in terms of their antimicrobial activity.

REFERENCES

1. Adams, C.J., Manley-Harris, M., Molan, P.C. The origin of methylglyoxal in New Zealand manuka (*Leptospermum scoparium*) honey. *Carbohydrate Res.*, 2009; **344**: 1050-1053.
2. Agoramorthy, G., Chandrasekaran, M., Venkatesalu, V., Hsu, M.J. Antibacterial and antifungal activities of fatty acid methyl esters of the blind-your-eye mangrove from India. *Braz J Microbiol.*, 2007; **38**:739-742.
3. Alfred, T. "Terpenoids" in Ullmann's Encyclopedia of Industrial Chemistry, Wiley VCH, Weinheim, 2002; doi:10.1002/14356007.
4. Altieri, C., Cardillo, D., Bevilacqua, A., Singaglia, M. Inhibition of *Aspergillus ssp.* and *Penicillium spp.* by fatty acids and their monoglycerides. *J Food Protect.*, 2007; **70**: 1206-1212.
5. Altuner, E.M. Bazi karayosunu türlerinin antimikrobiyal aktivitesinin belirlenmesi, Ph. D., Ankara Üniversitesi, Fen Bilimleri Enstitüsü, Ankara. 2008.

6. Altuner, E.M. Investigation of antimicrobial activity of *P. granatum* L. fruit peel ash used for protective against skin infections as folk remedies especially after male circumcision. *African J Microbiol Res*, 2011;**5**(20): 3339-3342.
7. Altuner, E.M., Akata, I. Antimicrobial activity of some macrofungi extracts. *SAÜ Fen Bilimleri Dergisi*, 2010; **14**, 45-49.
8. Altuner, E.M., Akata, I., Canli, K. *In vitro* antimicrobial screening of *Bovista nigrescens* (Pers.). *Kastamonu Uni J For Facul*, 2012a; **12**: 90-96.
9. Altuner, E.M., Akata, I., Canli, K. *In vitro* antimicrobial screening of *Cerena unicolor* (Bull.) Murrill (Polyporaceae Fr. Ex Corda). *Fresenius Environment Bull*, 2012b; **21**(1B): 3704-3710.
10. Altuner, E.M., Canli, K. *In vitro* antimicrobial screening of *Hypnum andoi* A.J.E. Sm. *Kastamonu Uni J For Facul*, 2012; **12**, 97-101.
11. Altuner, E.M., Ceter, T., Bayar, E., Aydin, S., Arici, F., Suleymanoglu, G., Edis, A. Investigation on antimicrobial effects of some moss species collected From Kastamonu Region. *Commun. Fac. Sci. Univ. Ank. Series C*, 2011a; **23**: 33-43.
12. Altuner, E.M., Çeter, T., Demirkapi, D., Ozkay, K., Hayal, U., Eser, G. Investigation on Antimicrobial Effects of Some Lichen Species Collected From Kastamonu Region. *Commun. Fac. Sci. Univ. Ank. Series C*, 2011b; **23**(1-2): 21-31.
13. Altuner, E.M., Çeter, T., Islek, C. Investigation of antifungal activity of *Ononis spinosa* L. ash used for the therapy of skin infections as folk remedies. *Mikrobiyol Bul*, 2010; **44**: 633-639.
14. Altuner, E.M., Çetin, B. Antimicrobial activity of *Thuidium delicatulum* (Bryopsida) extracts. *Kafkas Üniversitesi, Fen Bilimleri Enstitüsü Dergisi*. 2009; **2**: 85-92.
15. Altuner, E.M., Çetin, B., Çökmüş, C. Antimicrobial Screening of Some Mosses Collected From Anatolia, *Pharmacog Mag*, 2010a; **6**: 56.
16. Altuner, E.M., Çetin, B., Çökmüş, C. *Isotechium alopecuroides* Türünün Antimikrobiyal Aktivitesi Üzerine Lokasyon Parametresinin Etkisi, Ecology 2010 *Symposium Proceedings*, 2010b; p.96.
17. Altuner, E.M., Çetin, B., Çökmüş, C. Antimicrobial activity of *Tortella tortulosa* (Hedw.) Limpr. Extracts. *Kast Uni J For Facul*, 2010c; **10**: 111-116.
18. Altuner, E.M., Islek, C., Çeter, T., Alpas, H. High Hydrostatic Pressure Extraction of Phenolic Compounds from *Maclura pomifera* fruits, *Afr J Biotechnol*, 2012c; **11**(4): 930-937.
19. Andrews, J.M. BSAC standardized disk susceptibility testing method (version 6). *J Antimicrob Chemother*, 2003; **60**: 20-41.
20. Aoyagi, N., Kimura, R., Murata, T. Studies on *Passiflora incarnata* dry extract. I. Isolation of maltol and pharmacological action of maltol and ethyl maltol. *Chem Pharm Bull.*, 1974; **22**: 1008-1013.
21. Aytemir, M.D., Çalis, Ü., Özalp, M. Synthesis and Evaluation of Anticonvulsant and Antimicrobial Activities of 3-Hydroxy-6-methyl-2-substituted 4H-Pyran-4-one Derivatives. *Arch. Pharm. Pharm. Med. Chem.*, 2004; **337**: 281-288.
22. Bäcker, C., Wende, K., Meyer, U., Lindequist, U. Chemical and biological investigations of Manuka honey. *Planta Med*, 2010; **76** - P502.
23. Balamurugan, R., Duraipandiyam, V., Ignacimuthu, S. Antidiabetic activity of β -sitosterol isolated from *Lippia nodiflora* L. in streptozotocin induced diabetic rats. *Eur J Pharmacol*, 2011; **667**: 410.
24. Basile, A., Vuotto, M.L., Ielpo, T.L., Moscatiello, V., Ricciardi, L., Giordano, S., Cobianchi, R.C. Antibacterial activity in *Rhynchostegium riparoides* (Hedw.) Card. Extract (Bryophyta). *Phytother Res*, 1998; **12**: 146-148.
25. Batovska, D.I., Todorova, I.T., Tsvetkova, I.V., Najdenski, H.M. Antibacterial study of the medium chain fatty acids and their 1-mono-glycerides: individual effects and synergistic relationship. *Pol J Microbiol*, 2009; **58**(1), 43-47.
26. Bazes, A., Silkina, A., Douzenel, P., Faÿ, F., Kervarec, N., Morin, D., Berge, J.P., Bourgougnon, N. Investigation of the antifouling constituents from the brown alga *Sargassum muticum* (Yendo) Fensholt. *J Appl Phycol*. 2009; **21**(4): 395-403.
27. Budavari, S. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (12th ed.), Merck, 1996; ISBN 0911910123, 3225.
28. Budavari, S. The Merck index. 11th Edition. Merck & Co., Rahway, NJ, 1989.
29. Carballeira, N.M., O'Neil, R., Parang, K. Racemic and optically active 2-methoxy-4-oxatetradecanoic acids: novel synthetic fatty acids with selective antifungal properties. *Chem Phys Lipids*, 2005, **136**: 47-54.
30. Chakraborty, D., Shah, B. Antimicrobial, antioxidative and antihemolytic activity of piper betel leaf extracts. *Inter J Pharma Pharmaceut Sci*. 3, **Suppl 3**, 2011; 192-199.
31. Clifton, P. Lowering cholesterol - A review on the role of plant sterols. *Australian Family J PURE APPL MICROBIO*, **8**(4), AUGUST 2014.

- Physician*. 2009; **38** (4): 218-21.
32. Cosentino, S., Barra, A., Pisano, B., Cabizza, M., Pirisi, F.M., Palmas, F. Composition and antimicrobial properties of Sardinian Juniperus essential oils against foodborne pathogens and spoilage microorganisms. *J Food Prot.*, 2003; **66**(7):1288-91.
 33. De Boer, A.S., Diderichsen, B. On the safety of *Bacillus subtilis* and *B. amyloliquefaciens*: a review. *Appl. Microbiol. Biotechnol.*, 1991; **36**: 1-4.
 34. Erdogrul, Ö.T. Antibacterial Activities of Some Plant Extracts Used in Folk Medicine. *Pharmaceut Biol*, 2002; **40**: 269-273.
 35. Fassihi, A., Abedi, D., Saghaie, L., Sabet, R., Fazeli, H., Bostaki, G., Deilami, O., Sadinpour, H. Synthesis, antimicrobial evaluation and QSAR study of some 3-hydroxypyridine-4-one and 3-hydroxypyran-4-one derivatives. *Eur J Med Chem.*, 2009; **44**(5):2145-57.
 36. Feldlaufer, M.F., Lusby, W.R., Knox, D.A., Shimanuki, H. Isolation and identification of linoleic acid as an antimicrobial agent from the chalkbrood fungus, *Ascosphaera apis*. *Apidologie*, 1993; **24**: 89-94.
 37. Galieni, P., Bigazzi, C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of *Bacillus subtilis*. *J. Clin. Microbiol.*, 1998; **36**: 325-326.
 38. Gallina, G., Ferretti, G., Merlanti, R., Civitareale, C., Capolongo, F., Draisci, R., Montesissa, C. Boldenone, Boldione, and Milk Replacers in the Diet of Veal Calves: The Effects of Phytosterol Content on the Urinary Excretion of Boldenone Metabolites. *J. Agric. Food Chem.*, 2007; **55** (20): 8275-8283.
 39. Glover, D.E., Whittemore, M.S., Bryant, S.D. Methods and compositions for controlling biofouling using polyglycol fatty acid esters. International Patent Application WO 97/11912. 1997.
 40. Goldman, L., Wittgenstein, E., Blaney, D., Goldman, J., Sawyer, F. Studies of some physical properties of the dihydroxyacetone color complex, *J. Invest. Dermatol.*, 1961; **36**: 233-4. PMID 13706567.
 41. Gunstone, F.D., Harwood, J.L., Dijkstra, A.J. *The Lipid Handbook with Cd-Rom*. 3rd ed. Boca Raton: CRC Press, 2007.
 42. Hammer, K.A., Carson, C.F., Riley, T.V. Antimicrobial activity of essential oils and other plant extracts. *J Appl Microbiol*, 1999; **86**: 985-990.
 43. Hazell, S.L., Graham, D.Y. Unsaturated fatty acids and viability of *H. (Campylobacter) pylori*. *J. Clin. Microbiol.*, 1990; **28**: 1060-1061.
 44. Hidron, A.I., Edwards, J.R., Patel, J. "NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007". *Infect Control Hosp Epidemiol.*, 2008; **29**: 996-1011.
 45. Hossain, M.A., Rahman, A. Chemical composition of bioactive compounds by GC-MS screening and antifungal properties of crude extracts of cabbage samples. *Asian J. Biotechnol.*, 2011; **3**: 68-76.
 46. Huang, C.B., George, B., Ebersole, J.L. Antimicrobial activity of n-6, n-7 and n-9 fatty acids and their esters for oral microorganisms. *Arch Oral Biol.*, 2011; **55**(8): 555-560.
 47. Ilhan, S., Savaroglu, F., Colak, F., Filik Iscen, C., Erdemgil, F.Z. Antimicrobial activity of *Palustriella commutata* (Hedw.) Ochyra extracts (Bryophyta), *Turk J. of Biol.*, 2006; **30**: 149-152.
 48. Inoue, Y., Hada, T., Shiraishi, A., Hirose, K., Hamashima, H., Kobayashi, S. Biphasic effects of geranylgeraniol, teprenone, phytol on the growth of *S. aureus*. *Antimicrob. Agents. Chemother*. 2005; **49**: 1770-1774.
 49. Kabara, J.J., Swieczkowski, D.M., Conley, A.J., Tuant, J.P. Fatty acids and derivatives as antimicrobial agents. *Antimicrob Agents Chemother*; 1972; **2**: 23-28.
 50. Karimi, E., Jaafar, H.Z.E. HPLC and GC-MS Determination of Bioactive Compounds in Microwave Obtained Extracts of Three Varieties of *Labisia pumila* Benth. *Molecules*, 2011; **16**: 6791-6805.
 51. Khalid, A., Waseem, A., Saadullah, M., Rehman, U.U., Khiljee, S., Sethi, A., Asad, M.H.H.B., Waqas, M.K., Murtaza, G. Antibacterial activity analysis of extracts of various plants against gram -positive and -negative bacteria. *Afr J Pharma Pharmacol*, 2011; **5**(7), 887-893
 52. Kimura, R., Matsui, S., Ito, S., Aimoto, T., Murata, T. Central depressant effects of maltol analogs in mice, *Chem. Pharm. Bull.*, 1980; **28**, 2570-2579.
 53. Knapp, H.R., Melly, M.A. Bactericidal effects of polyunsaturated fatty acids. *J. Infect. Dis.*, 1986; **154**: 84-94.
 54. Kumar, P.P., Kumaravel, S., Lalitha, C. Screening of antioxidant activity, total phenolics and GC-MS study of *Vitex negundo*. *African J Biochem Res.*, 2010; **4**(7):191-195.
 55. Liu, S., Weibin, R., Jing, L., Hua, X., Jingan, W., Yubao, G., Jingguo, W. Biological control of phytopathogenic fungi by fatty acids.

- Mycopathol.* 2008; **166**: 93-102.
56. Lis-Balchin, M., Deans, S.G. Bioactivity of selected plant essential oils against *Listeria monocytogenes*. *J Appl Bacteriol*, 1997; **82**, 759-762.
 57. Lukowski, G., Lindequist, U., Mundt, S., Kramer, A., Jülich, W.D. Inhibition of Dermal MRSA Colonization by Microalgal Micro- and Nanoparticles. *Skin Pharmacol Physiol.*, 2008; **21**: 98-105.
 58. Mahida, Y., Mohan, J.S.S. Screening of plants for their potential antibacterial activity against *Staphylococcus* and *Salmonella* spp. *Nat Prod Radian*, 2007; **6**: 301-305.
 59. Mahasneh, A.M., El-Oqlah, A.A. Antimicrobial activity of extracts of herbal plants used in the traditional medicine of Jordan. *J Ethnopharmacol*, 1999; **64**: 271-276.
 60. Mavric, E., Wittmann, S., Barth, G., Henle, T. Identification and quantification of methylglyoxal as the dominant antibacterial constituent of Manuka (*Leptospermum scoparium*) honeys from New Zealand. *Mol Nutr Food Res.*, 2008; **52**: 483-489.
 61. McClelland, M., Sanderson, K.E., Spieth, J., Clifton, S.W., Latreille, P., Courtney, L., Porwollik, S., Ali, J., Dante, M., Du, F., Hou, S., Layman, D., Leonard, S., Nguyen, C., Scott, K., Holmes, A., Grewal, N., Mulvaney, E., Ryan, E., Sun, H., Florea, L., Miller, W., Stoneking, T., Nhan, M., Waterston, R., Wilson, R.K. Complete genome sequence of *Salmonella enterica* serovar Typhimurium LT2. *Nature*, 2001; **413**: 852-856.
 62. McGaw, L.J., Jäger, A.K., Van Staden, J. Isolation of antibacterial fatty acids from *Schotia brachypetala*. *Fitoter.*, 2002; **73**: 431-433.
 63. McGinty, D., Letizia, C.S., Api, A.M. Fragrance material review on phytol. *Food Chem Toxicol*, 2010; **48**(3), 59-63.
 64. Murray, B.E. "The life and times of the Enterococcus". *Clin Microbiol Rev.*, 1990; **3**: 46-65.
 65. Nalina, T., Rahim, Z.H.A. The crude aqueous extract of *Piper betel* L. and its antibacterial effect towards *Streptococcus mutans*. *American J Biotechnol Biochem.* 2007; **3**: 10-15.
 66. Narasimhan, B., Mourya, V., Dhake, A. Design, synthesis, antibacterial, and QSAR studies of myristic acid derivatives. *Bioorg Medicin Chem Letters*, 2006; **16**: 3023-3029.
 67. Nikaido, H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. *Clin Infect Dis*, 1998; **27**: 32-41.
 68. Onbasli, D., Altuner, E.M., Çelik, G.Y. *Mnium marginatum* Özütlelerinin Antimikrobiyal Aktivitesi, Kastamonu Üniversitesi, *Orman Fakültesi Dergisi*, 2011; **11**: 205-208.
 69. Onbasli, D., Yuvali Çelik G., Altuner, E.M., Altinsoy, B., Aslim, B. *In vitro* antimicrobial, antioxidant, and antibiofilm activities of *Bryum capillare*, a bryophyte sample. *Current Opinion in Biotechnology*, 2013; **24** (Supplement 1): 113.
 70. Oztopcu-Vatan, P., Savaroglu, F., Filik Iscen, C., Kabadere, S., Ilhan, S., Uyar, R. Antimicrobial and antiproliferative activities of *Homalothecium sericeum* (Hedw.) Schimp. Extracts. *Fresen. Environ. Bullett.*, 2011; **20**, 461-466.
 71. Padmini, E., Valarmathi, A., Usha Rani, M. Comparative analysis of chemical composition and antibacterial activities of *Mentha spicata* and *Camellia sinensis*. *Asian J. Exp. Biol. Sci.*, 2010; **1**(4), 772-781.
 72. Panda, S., Jafri, M., Kar, A., Mehta, B.K. Thyroid inhibitory, antiperoxidative and hypoglycemic effects of stigmaterol isolated from *Butea monosperma*. *Fitoter.* 2009; **80**(2): 123-126.
 73. Pauli, A. Anticandidal low molecular compounds from higher plants with special reference to compounds from essential oils, 2006; 223-268.
 74. Párraga, I., López-Torres, J., Andrés, F., Navarro, B., del Campo, J.M., García-Reyes, M., Galdón, M.P., Lloret, A., Precioso, J.C., Rabanales, J. Effect of plant sterols on the lipid profile of patients with hypercholesterolaemia. Randomised, experimental study. *BMC Complemen Alternat Med*, 2011; **11**: 73.
 75. PBS. Nova Transcripts: Forgotten Genius, 2007; http://www.pbs.org/wgbh/nova/transcripts/3402_julian.html.
 76. Prachayasittikul, S., Buttrawong, K., Worachartcheewan, A., Ruchirawat, S., Prachayasittikul, V. Isolation of bioactive metabolites from root extracts of *Polyalthia debilis*. *Eur J Sci Res.*, 2009; **38**(4): 596-603.
 77. Prachayasittikul, S., Worachartcheewan, A., Yainoy, S., Lomchoey, N., Kittiphacharin, P., Ruchirawat, S., Prachayasittikul, V. Antioxidant and antimicrobial activities of *Saraca thaipingensis* Cantley ex Prain. *Asian Pacific J Trop Biomed*, 2012; **S796-S799**.
 78. Queck, S.Y., Otto, M. *Staphylococcus epidermidis* and other Coagulase-Negative Staphylococci. *Staphylococcus: Molecular Genetics*. Caister Academic Press, 2008.
 79. Raman, B.V., Samuel, L.A., Pardha Saradhi, M., Narashimha Rao, B., Naga Vamsi Krishna, A., Sudhakar, M., Radhakrishnan, T.M. Antibacterial, antioxidant activity and gc-ms analysis of *Eupatorium odoratum*. *Asian J Pharmaceut Clin Res.* 5, 2012; **2**: 99-106.
 80. Reynolds, J.E.F. Martindale - the Extra J PURE APPL MICROBIO, **8**(4), AUGUST 2014.

- Pharmacopoeia, thirty first ed. Royal Pharmaceutical Society of Great Britain, London, 1996.
81. Revathi, S.L., Suresh Kumar, P., Sudarshana Deepa, V., Senthil Kumar, J., Anitha Janet Roshni, Y. Antimicrobial activity of *Andrographis serpyllifolia* (Rohl.ex.Vahl) Wright. *Internat J Pharmaceut Sci Health Care*, 2012; **2**(1): 17-31.
 82. Risk, M., Harrison, P., Lewis, J. Wood preserving composition. International Patent Application WO 97/34747, 1997.
 83. Salyers, A., Whitt, D. Bacterial Pathogenesis: A Molecular Approach, 2nd ed. Washington, D.C.: ASM Press, 2002.
 84. Samejo, M.Q., Ndukwe, G.I., Burdi, D.K., Bhangar, M.I., Khan, K.M. Isolation and crystal structure of maltol from *Abies pindrow*, *J Medic Plants Res*, 2009; **3**(2): 55-60.
 85. Samidurai, K., Saravanakumar, A. Antibacterial Activity of *Pemphis Acidula* Forst. *Global J Pharmacol*, 2009; **3**: 113-115.
 86. Sarac, N., Ugur, A. Antimicrobial activities and usage in folkloric medicine of some Lamiaceae species growing in Mugla, Turkey. *EurAsian J BioSci*, 2007; **4**: 28-37.
 87. Saroya, A.S. Herbalism, Phytochemistry and Ethnopharmacology. Herbal Consultant, Punjab, India, 2011.
 88. Savaroglu, F., Filik-Iscen, C., Oztopcu-Vatan, P., Kabadere, S., Ilhan, S., Uyar, R. Determination of antimicrobial and antiproliferative activities of the aquatic moss *Fontinalis antipyretica* Hedw, *Turk. J. Biol.*, 2011a; **35**: 361-369.
 89. Savaroglu, F., Filik Iscen, C., Ilhan, S. An Evaluation of the Antimicrobial Activity of Some Turkish Mosses, *J Med Plants Res*, 2011b; **5**: 3286-3292.
 90. Seidel, V., Taylor, P.W. *In vitro* activity of extracts and constituents of *Pelagonium* against rapidly growing mycobacteria. *Int. J. Antimicrob. Agen.*, 2004; **23**: 613-619.
 91. Silici, S., Koc, A.N. Comparative study of in vitro methods to analyse the antifungal activity of propolis against yeasts isolated from patients with superficial mycoses. *Letters in Appl Microbiol*, 2006; **43**: 318-324.
 92. Singh, B., Sharma, R.A., Vyas, G.K., Sharma, P. Estimation of Phytoconstituents from *Cryptostegia grandiflora* (Roxb.) R. Br. *In vivo* and *In vitro*. II. Antimicrobial Screening. *J Med Plants Res*, 2011; **5**(9): 1598-1605.
 93. Skrivanova, E., Marounek, M., Benda, V., Brezina, P. Susceptibility of *Escherichia coli*, *Salmonella sp.* and *Clostridium perfringens* to organic acids and monolaurin. *Veterinar Medic*, 2006; **51**(3): 81-88.
 94. Smith, A.J.E. The Moss Flora of Britain and Ireland. 2nd Edition. London, England: Cambridge University Press, 2004.
 95. Soulimani, R., Younos, C., Jarmouni, S., Bousta, D., Misslin, R., Mortier, F. Behavioral effects of *Passiflora incarnata* L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. *J Ethnopharmacol*, 1997; **57**:11-20.
 96. Sun, C.Q., O'Connor, C.J., Robertson, A.M. Antibacterial actions of fatty acids and monoglycerides against *H. pylori*. *FEMS Immunol. Med. Microbiol.* 2003; **36**: 9-17.
 97. Sundararaman, P., Djerassi, C. A convenient synthesis of progesterone from stigmasterol. *J Org Chem.*, 1977; **42**(22): 3633-3634.
 98. Tsuchida, M., Morishita, Y. Antibacterial Activity and Bacterial Degradation of Linoleic Acid Hydroperoxide. *Bifidobacteria Microflora*, 1995; **14** (2), 67-74.
 99. Uma, M., Jothinayaki, S., Kumaravel, S., Kalaiselvi, P. Determination of Bioactive Components of *Plectranthus amboinicus* Lour by GC-MS Analysis. *NY Sci J*, 2011; **4**(8): 66-69.
 100. Veljic, M., Tarbuk, M., Marin, P.D., Ciric, A., Sokovic, M., Marin, M. Antimicrobial Activity of Methanol Extracts of Mosses from Serbia. *Pharmaceut Biol*, 2008; **46**: 871-875.
 101. Villegas, M.V., Quinn, J.P. An update on antibiotic-resistant gram-negative bacteria, *Infections in Medicine*, 2004; **21**: 595-599.
 102. Walters, D., Raynor, L., Mitchell, A., Walker, R., Walker, K. Antifungal activities of four fatty acids against plant pathogenic fungi. *Mycopathol.* 2004; **157**: 87-90.
 103. Wittgenstein, E., Berry, H.K. Staining of skin with dihydroxyacetone, *Science*, 1960; **132** (3431): 894-5.
 104. Wittgenstein, E., Guest, G.M. Biochemical effects of dihydroxyacetone, *J. Invest. Dermatol.*, 1961; **37** (5): 421-6.
 105. Zhang, Z.F., Zhou, X.Y. GC/MS Analysis on Benzene/Alcohol Extractives of *Manglietia glauca* Leaves for Biomedicine Engineering, *Advan Mat Res*, 2011; **213**: 475.
 106. Zheng, C.J., Yoo, J.S., Leeb, T.G., Cho, H.Y., Kim, Y.H., Kim, W.G. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. *FEBS Letters*, 2005; **579**: 5157-5162.